Piramal Pharma Limited Reports Financial Results for Q4 and Full Year of FY26
Piramal Pharma Limited Reports Financial Results for Q4 and Full Year of FY26
Piramal Pharma Limited, a prominent name in the global pharmaceutical and health sector, has announced its financial results for the fourth quarter (Q4) and full year ending March 31, 2026. The announcement, made on April 28, 2026, indicates a mixed performance across its various business segments amid challenging external conditions.
Financial Overview
The company's consolidated revenue from operations for Q4 was ₹2,752 Crores, showing a slight decrease from ₹2,754 Crores in the same quarter last year. Overall, for FY26, the revenue totaled ₹8,869 Crores, marking a 3% reduction from the previous fiscal year, where revenue stood at ₹9,151 Crores. The contraction was mainly attributed to inventory destocking, slower early-stage order inflows, and reduced traction, specifically in inhalation anesthesia markets outside the US.
Key Financial Metrics
- - CDMO (Contract Development and Manufacturing Organization): Q4 revenue dropped to ₹1,708 Crores, down 4% year-over-year (YoY). Total revenues for FY26 fell by 10% to ₹4,915 Crores.
- - CHG (Complex Hospital Generics): This segment experienced a positive shift, with revenue increasing by 7% YoY in Q4 to reach ₹755 Crores and a growth of 3% for the full year at ₹2,703 Crores.
- - PCH (Piramal Consumer Healthcare): Showed robust performance, achieving a revenue growth of 17% in Q4 with ₹320 Crores, and a full-year revenue growth of 17%, totaling ₹1,274 Crores.
Despite facing revenue challenges, the company managed to maintain certain margins through cost optimization strategies. The annual EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) stood at ₹1,135 Crores, a significant drop of 28% from FY25. The EBITDA margin for FY26 was reported at 13%, down from 17% in FY25.
Notable Changes
Piramal Pharma also faced an exceptional item resulting in a net loss after exceptional items of ₹9 Crores for Q4, contrasted against a profit of ₹154 Crores in Q4 FY25. However, the net profit margin before extraordinary items reflected a year-on-year growth of 9%. A significant aspect leading to the losses was identified as an impairment loss of ₹176 Crores related to development assets. The management addressed this by reassessing market conditions, concluding that further capital deployment for the asset was unviable.
Strategic Initiatives
Nandini Piramal, the Chairperson, emphasized that FY26 represented a transitional phase for the firm. Despite adversities, the latter part of the year reflected improvements, particularly in biopharma funding since September 2025. This resurgence is expected to bolster RFPs (Request for Proposals) and order inflow, notably within the CDMO sector. Furthermore, the acquisition of the Kenalog® brand is anticipated to enhance the CHG division's offerings while also positioning the Consumer Healthcare business for sustained growth through e-commerce expansion.
Business Segment Highlights
1. CDMO: There’s increased interest in differentiated products with US biopharma funding growing significantly. Plans are in place for further capital expenditure amounting to $90 Million for infrastructural expansions.
2. CHG: The recent acquisition of Kenalog® is expected to broaden revenue streams with minimal added costs. The company maintains a significant market share in the inhalation anesthesia category.
3. PCH: The consumer healthcare segment thrives with a 24% YoY growth, contributing substantially to company revenues. The brand strategy focuses on premiumization and expanding high-margin product channels.
Piramal Pharma is on track to host an investor conference call to discuss these results, providing further insights into the financial performance and strategic goals for the upcoming fiscal year. The company remains optimistic about driving future growth post-transition and further enhancing profitability across all business segments.
For further information on the financial performance and strategic direction of Piramal Pharma Limited, follow their updates on LinkedIn.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.